Copyright
©The Author(s) 2024.
World J Diabetes. Apr 15, 2024; 15(4): 654-663
Published online Apr 15, 2024. doi: 10.4239/wjd.v15.i4.654
Published online Apr 15, 2024. doi: 10.4239/wjd.v15.i4.654
Data | NVG group (n = 21) | No-NVG group (n = 130) | χ2/t | P value | |
Sex, n (%) | Male | 12 (57.14) | 78 (60.00) | 0.061 | 0.084 |
Female | 9 (42.86) | 52 (40.00) | |||
Age (mean ± SD, yr) | 57.58 ± 8.12 | 55.21 ± 10.27 | 1.007 | 0.315 | |
BMI (mean ± SD, kg/m2) | 22.28 ± 3.16 | 22.24 ± 3.41 | 0.050 | 0.959 | |
Diabetes duration (mean ± SD, yr) | 10.23 ± 3.11 | 10.37 ± 3.46 | 0.174 | 0.861 | |
Diabetes type, n (%) | Type 1 | 4 (19.05) | 11 (8.46) | 1.236 | 0.266 |
Type 2 | 17 (80.95) | 119 (91.54) | |||
DR severity | Nonproliferative | 8 (38.10) | 64 (49.23) | 0.899 | 0.343 |
Proliferative | 13 (61.90) | 66 (50.77) | |||
Complicated with hypertension, n (%) | Yes | 14 (66.67) | 59 (45.38) | 3.279 | 0.070 |
No | 7 (33.33) | 71 (54.62) | |||
Combined hyperlipidemia, n (%) | Yes | 13 (61.90) | 61 (46.92) | 1.624 | 0.203 |
No | 8 (38.10) | 69 (53.08) | |||
Preoperative intraocular pressure (mean ± SD, mmHg) | 15.23 ± 2.81 | 15.26 ± 2.87 | 0.044 | 0.964 | |
Operation time (mean ± SD, min) | 125.42 ± 16.85 | 120.13 ± 15.73 | 1.416 | 0.158 | |
Intraocular pressure 7 d after surgery (mean ± SD, mmHg) | 19.15 ± 2.25 | 18.16 ± 2.41 | 1.762 | 0.080 | |
Number of vitrectomies, n (%) | First time | 15 (71.43) | 110 (84.62) | 2.206 | 0.138 |
Not the first time | 6 (28.57) | 20 (15.38) | |||
Intraocular filler, n (%) | Silicone oil | 3 (14.29) | 38 (29.23) | 1.356 | 0.244 |
BSS or gas fill | 18 (85.71) | 92 (70.77) | |||
Combined cataract surgery, n (%) | Yes | 12 (57.14) | 52 (40.0) | 2.176 | 0.140 |
No | 9 (42.86) | 78 (60.0) | |||
Posterior capsular integrity in combined cataract surgery, n (%) | Complete | 15 (71.43) | 128 (98.46) | 6.441 | < 0.001 |
Defect | 6 (28.57) | 12 (9.23) | |||
Ipilateral carotid artery stenosis ≤ 25.0%, n (%) | Yes | 4 (19.05) | 6 (4.62) | 6.090 | < 0.001 |
No | 17 (80.95) | 124 (95.38) | |||
Residual retinal non-perfusion area, n (%) | Yes | 7 (33.33) | 17 (13.08) | 5.549 | < 0.001 |
No | 14 (66.67) | 113 (86.92) | |||
Preoperative anti-VEGF drug therapy, n (%) | Yes | 3 (14.29) | 42 (32.31) | 2.012 | 0.156 |
No | 18 (85.71) | 88 (67.69) | |||
Preoperative VEGF (mean ± SD, pg/mL) | 312.01 ± 29.29 | 275.64 ± 36.92 | 4.297 | < 0.001 | |
HbA1C (mean ± SD, %) | 9.31 ± 1.29 | 8.42 ± 1.07 | 3.434 | < 0.001 | |
Serum IL-6 (mean ± SD, pg/mL) | 3.51 ± 0.67 | 3.15 ± 0.85 | 1.848 | 0.066 | |
Serum IL-10 (mean ± SD, pg/mL) | 2.62 ± 0.42 | 2.74 ± 0.57 | 0.923 | 0.357 | |
Serum TNF-α (mean ± SD, pg/mL) | 10.88 ± 3.41 | 9.52 ± 3.06 | 1.860 | 0.064 | |
Aqueous IL-6 (mean ± SD, pg/mL) | 54.54 ± 15.81 | 39.14 ± 11.10 | 5.526 | < 0.001 | |
Aqueous IL-10 (mean ± SD, pg/mL) | 9.91 ± 2.77 | 7.94 ± 1.92 | 4.067 | < 0.001 | |
Aqueous TNF-α (mean ± SD, pg/mL) | 5.00 ± 1.26 | 3.91 ± 0.75 | 5.499 | < 0.001 |
- Citation: Shi Y, Zhang YX, Jiao MF, Ren XJ, Hu BJ, Liu AH, Li XR. Construction and validation of a neovascular glaucoma nomogram in patients with diabetic retinopathy after pars plana vitrectomy. World J Diabetes 2024; 15(4): 654-663
- URL: https://www.wjgnet.com/1948-9358/full/v15/i4/654.htm
- DOI: https://dx.doi.org/10.4239/wjd.v15.i4.654